Home Applications 205626 Application 205626
Type NDA
Sponsor MICRO LABS Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE TABLET;ORAL 150MG;200MG;300MG Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N205626-001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE 150MG;200MG;300MG TABLET / ORAL RLD 2018-08-13
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N205626-001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE 150MG;200MG;300MG TABLET / ORAL RLD 2018-08-13 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N205626-001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE 150MG;200MG;300MG TABLET / ORAL RLD 2018-08-13 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N205626-001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE 150MG;200MG;300MG TABLET / ORAL RLD 2018-08-13 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N205626-001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE 150MG;200MG;300MG TABLET / ORAL RLD 2018-08-13 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N205626-001 LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE 150MG;200MG;300MG TABLET / ORAL RLD 2018-08-13 a50c72e98297…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 1 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 42571-166 Lamivudine, Nevirapine, and Zidovudine Lamivudine, Nevirapine, and Zidovudine Micro Labs Limited NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 56557 ORIG 2018-11-26 55213 ORIG 2018-08-20 55179 ORIG 2018-08-15 55178 ORIG 2018-08-15 63009 ORIG 1900-01-01 63008 ORIG 1900-01-01 63007 ORIG 1900-01-01